Reading the tape
NASDAQ: NBIX
Neurocrine Biosciences, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
Market Cap
$13.46B
52w High
$160.18
52w Low
$115.66
P/E
27.87
Volume
1.18M
Outstanding Shares
100.36M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 22.16%Revenue (TTM): 21.45%FCF (TTM): 34.37%P/FCF: 0th pct
What changed
The stock rose 22.16% over the last year. Revenue grew 21.45% over the trailing twelve months. Operating margin moved from 24.22% to 21.64%. Free cash flow grew 34.37% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 0th percentile of their historical P/FCF range.
What would invalidate this read
Operating margin is at 21.64%. Revenue grew 21.45% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders.
CEOKyle W. Gano
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees1,800
IPO dateMay 23, 1996
Valuation
Forward P/E—
EV/EBITDA20.72
Enterprise value$13.81B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth28.33%
Gross margin98.18%▼0.38%vs FY2024
Operating margin21.64%▼10.65%vs FY2024
ROE14.71%▲11.63%vs FY2024
Analyst consensus
RatingBuy
Target price$178.09▲32.83%
32
Buy
5
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est $1.68 · Revenue est $768.25M
View